Latest filing published 02 Apr 2026 for Processa Pharmaceuticals, Inc., €1,728. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
James R. Neal, listed as chief executive, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Akari Therapeutics Plc, XOMA Royalty Corp and Processa Pharmaceuticals, Inc. Over a trading history stretching from 25 June 2021 to 31 March 2026, the count stands at 10 filings.
On the open market, the record shows 1 purchase worth €1,728 and 1 sale worth €200k. The net balance comes to €199k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 share grants and 4 option exercises. 2026 to date brings 1 purchase and no sales.
The newest entry dates from 2 April 2026: an open-market purchase of €1,728, in Processa Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations